Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company that entered the public markets through its December 2019 merger with Health Sciences Acquisitions Corporation, a blank-check vehicle sponsored by OrbiMed Advisors and focused on the healthcare and life sciences sector. The company, which is developing FcRn inhibitor therapies targeting autoimmune diseases, filed an 8-K current report with the SEC on August 2, 2021, under accession number 0001764013-21-000061, continuing its ongoing disclosure obligations as a post-merger public company. As of the filing date, Immunovant remained an active clinical-stage issuer in the biopharmaceutical space. Visit SpacDesk and sign up for full data, including filing histories, sponsor profiles, and post-merger performance tracking across the SPAC universe.